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A B S T R A C T  
 
Background: Arthritis rheumatoid (AR) is a chronic inflammatory disease that mainly 
affects the joints. Decreased bone mass and osteoporosis are its complications. Several 
factors such as dietary calcium, disease activity, physical activity, vitamin D levels, steroids 
can affect bone mineral density values. Aim: The purpose of this study was to determine 
the relationship between disease activity, calcium levels and bone mineral densitometry 
in patients with arthritis rheumatoid. Methods: 23 AR patients based on the 2010 ACR 
criteria including the inclusion criteria with a cross sectional study approach that had bone 
mineral densitometry (BMD) data for the last 1 year. Blood samples were also taken to 
check the total calcium level, the characteristics of the baseline data were collected, and 
the disease activity was examined using the DAS 28 LED. The relationship between these 
factors and the bone mass density was analyzed using the Spearman test. The analysis 
result was considered significant if p <0.05. Results: The results showed that the basic 
characteristics of the subjects were 45,87 years old, body mass index 24,51 kg / m2, 
duration of illness 3,96 years, steroid dose 3,48 mg, disease activity 4.35 (moderate disease 
activity), anti CCP 333,87 U / ml, rheumatoid factor (RF) 10,18 IU / ml, methotrexate 12,17 
mg, leflunomide 20 mg. There was no significant relationship between serum calcium 
levels and disease activity with BMD. However, there was a significant relationship between 
age and BMI with BMD in the femur neck (p = 0,043), lumbar 3 (p = 0,017) and lumbar 4 (p = 
0,048). Conclusion: There is no relationship between disease activity and calcium levels 
with bone mass density values in AR patients except for age and BMI. 
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I N T R O D U C T I O N  
Rheumatoid arthritis (AR) is an 
autoimmune disease of the joints characterized 
by chronic and progressive systemic 
inflammation in which joint synovium are the 
main targets. Decreased bone mass and 
osteoporosis are complications in patients with 
AR. [1-4] Systemic chronic inflammation in AR has 
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a major role in decreasing bone mass and 
osteoporosis in patients with AR. [5-8] In AR, there 
is an overexpression of several inflammatory 
cytokines tumor necrosis factor (TNF-α), IL-1, IL-
6 and IL17 triggering osteoclast activation, 
differentiation and proliferation induced by 
receptor activator of nuclear factor Kβ-Ligand 
(RANKL) where activation osteoclasts will cause 
bone mineral reabsorption. Chronic systemic 
inflammation increases RANKL expression and 
reduces osteoprotegerin (OPG).[9-12] OPG is a 
soluble feed receptor for RANKL that inhibits 
both osteoclast differentiation and function. In 
chronic inflammation, inhibition of osteoclast 
activity occurs through the mechanism of 
decreasing OPG expression. [7, 10]  
It is known that localized and generalized 
reduction in bone mineral densitometry (BMD) is 
the main effect of increased osteoclast activity in 
AR. Dual-energy X-ray absorptiometry (DXA) is 
the gold standard for measuring BMD. DXA is a 
widely used technique to assess general and 
periarticular reduction in bone mineral density. 
DXA is able to measure the bone mineral density 
of integral cortical and trabecular areas of bone. 
[13-15]  
In patients with AR, calcium 
administration is very beneficial in maintaining 
bone health. It is widely known that in AR there is 
impaired calcium absorption. In addition, the 
long-term use of steroids results in decreased 
intestinal calcium absorption and increased 
renal excretion of calcium. In previous studies, it 
was found that calcium metabolism disorders in 
AR patients caused a decrease in blood calcium 
levels. [16, 17] 
In patients with AR, measurement of 
disease activity is very important because it 
reflects the patient's results and response to the 
therapy given. Persistently high disease activity 
can lead to permanent joint damage, disability, 
and even decreased life expectancy. Tightly 
controlled disease activity will improve the 
inflammatory process associated with AR and 
improve bone metabolism to form normal bone 
structure again not only in joints but also 
throughout the body. [18] 
 
M E T H O D S 
This study was conducted with a cross-
sectional study approach, conducted on AR 
patients aged 18-55 years who were diagnosed 
based on the 2010 ACR criteria for at least 1 year 
and the steroid dose used was less than 7,5 mg 
per day in the last 3 months, and the patient had 
already been done. BMD within a maximum of 1 
year and have agreed to the informed consent to 
participate in the study. The exclusion criteria 
included having malignancy, chronic kidney 
disease, systemic lupus erythematosus, chronic 
liver disease, diabetes mellitus, or having thyroid 
dysfunction. This research has received ethical 
permission from the Hospital Research Ethics 
Commission of dr. Saiful Anwar, General Hospital 
Malang. 
Characteristics of the patient's baseline 
data were taken consisting of name, age, weight, 
height, body mass index (BMI), duration of AR 
illness, rheumatoid factor (RF), anti-cyclic 
citrullinated peptide (anti-CCP), steroid dosage 
used, the dosage and type of DMARD treatment 
used by the patient. Disease activity was 
measured using a disease activity score 28 LED 
(DAS 28 LED). AR disease activity level was 
defined as low (DAS 28 ≤ 3,2), moderate (3,2 <DAS 
28 ≤ 5,1), or high (DAS 28> 5,1). Then, routine 
biochemical and blood tests were carried out to 
determine the calcium level and sedimentation 
rate (ESR).  
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All samples were examined 
enzymatically using an auto-analyzer located in 
the clinical pathology laboratory of Saiful Anwar 
General Hospital Malang. The serum level of 
biochemical parameters is determined by 
standard laboratory procedures. Serum calcium 
is considered normal 8,6–10,2 mg / dL. The serum 
calcium used was not adjusted according to the 
findings in previous studies. [20] Bone mass 
density (g/cm2) was measured by means of a DXA 
instrument at lumbar 1, lumbar 2, lumbar 3, 
lumbar 4, lumbar 1-4, and proximal femur 
(femoral neck, Ward's triangle, and femoral 
trochanter). Based on the World Health 
Organization (WHO) criteria, the T-score for bone 
density is at -1,0 to -2,5 osteopenia, a T-score ≤ -
2,5 is called osteoporosis and a T-score ≥ -1,0 is 
called normal. [21] 
All data are presented as means and 
standard deviation if the data is normally 
distributed or median and interquartile ranges if 
the data are not normally distributed. The 
relationship between data was tested with 
Pearson's or Spearman's correlation coefficient. 
A p value <0,05 was considered statistically 
significant. All statistical analyzes were 
performed with SPSS version 26 software. 
 
R E S U L T S 
The total research subjects who were the 
subjects were 23 people. With 18-55 years of age, 
those diagnosed with AR are at least 1 year old, 
with a steroid dose that is not more than 7,5 
mg/day for the last 3 months. There is no chronic 
liver disease, diabetes mellitus, chronic renal 
impairment, hyperthyroidism, malignancy and 
systemic lupus erythematosus. 
Based on Table 1 about the 
characteristics of the subject above, it is known 
that the mean age was 45,87 ± 12,77 years and 
the body mass index was obtained a mean of 
24,51 ± 4,55 kg / m2 which is included in the 
normal range. The mean serum calcium level was 
9,20 ± 0,36 mg / dL which is still within the normal 
range of calcium values. For the mean duration 
of AR illness suffered was 3,96 ± 2,46 years. The 
average dose of methotrexate drug consumed 
was 12,17 ± 4,15 mg per week. The average dose 
of steroid consumed per day was 3,48 ± 1,38 mg. 
Meanwhile, the average dose of leflunomide per 
week was 20 ± 8,44 mg. The patient's AR disease 
activity measured by the DAS 28 LED formula 
obtained a mean of 4,35 ± 1,42 which can be 
classified as moderate disease activity. 
 
Table 1. Characteristics of Subject 
Characteristics                   Subject (N=23) 
Age (years) 
IMT (Kg/m2) 
Calcium Level (mg/dL) 
Duration of RA (Years) 
Methotrexate dosage (mg) 
Steroid Dosage (mg) 
Leflunomide Dosage (mg) 
Anti-CCP Level (U/ml) 
Patient with CCP (+) 
Patient with CCP (-) 
Rheumatoid Factor (IU/ml) 
Patient with RF (+) 
Patient with RF (-) 
Activity of AR 
45,87 ± 12,77 
24,51±4,55 
9,20 ± 0,36 
3,96 ± 2,46 
12,17 ± 4,15 
3,48 ± 1,38 




10,18 ± 28,33 
21,73 % 
78,26 % 
4,35 ± 1,42 
Based on Table 2, the results of the 
proportion value classification of the BMD value 
based on the T-score on the femur neck were 
found to be normal patients as much as 0%, 
patients with osteopenia as much as 91,3%, and 
osteoporosis patients as much as 8,7%. The 
value of the proportion of classification of BMD 
values based on the T-score in lumbar 1-4 was 
obtained by 0% normal classification patients, 
65,22% osteopenia patients, and 34,78% 
osteoporosis patients. 
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Table 2. Percentage of BMD Classification 
Classification of 
BMD 








From the analysis of the correlation test 
between disease activity and calcium levels with 
BMD values in lumbar 1, lumbar 2, lumbar 3, 
lumbar 4, lumbar 1-4, and proximal femur 
(femoral neck, Ward's triangle, and femoral 
trochanter), there was no significant correlation. 
However, there was a significant correlation 
between age and BMD value on the femur neck (p 
= 0,043) and lumbar 4 (p = 0,048) with a negative 
correlation coefficient. There was a significant 
correlation between steroid dose and BMD value 
on the femur neck (p = 0,025) with a positive 
correlation coefficient. 
D I S C U S S I O N S  
AR is a chronic systemic autoimmune 
disease that primarily affects the joints. 
Decreased bone mass is one of the complications 
that occur.[22] The occurrence of osteoporosis 
and decreased BMD resulted in osteoporosis and 
decreased BMD was found in the spine and hips 
by 11% and 25% in AR patients, respectively.[14] 
The risk of osteoporosis in AR is 2 times higher 
than that of controls. The prevalence in various 
parts of the world is reported to be between 22% 
and 36%. [23] 
 In this study, it was found that there were 
no normal BMD in the patient both on the femur 
neck and at L1-4, osteopenia as much as 65,22% 
and osteoporosis as much as 34,78%, although 
from the patient's basic characteristics, the 
mean age of the patient was 45,87 years. This 
indicates a decrease in bone mass and 
osteoporosis. A substantial decrease in bone 
mass usually occurs around age 65 in men and 50 
years in women. Women can maintain their peak 
bone mass density until menopause. [24-26] These 
results are consistent with existing literature that 
AR increases the risk of decreased bone mass and 
osteoporosis. [22, 27] 
The osteoporosis rate was 34,78% and 
subjects who had osteopenia were 100% a high 
number. Several factors influenced the results, 
including the high disease activity, where in this 
study the disease activity of patients was 4,35 ± 
1,42 who were included in the moderate disease 
activity. Disease activity in this study has not yet 
reached the target, so inflammation that 
continues to eat will increase the risk of 
decreasing bone mass. Negative RF can also 
affect disease progression and activity in AR, 
negative RF is often associated with disease 
activity and higher progressivity so that the risk 
of decreased bone mass and osteoporosis 
increases.[28] Where in this study the research 
subjects had a negative dominant RF. The 
dominant anti-CCP factor was positive in this 
study, where anti-CCP based on previous studies 
correlated with the progression of AR disease. [29-
32] 
In this study, there was no significant 
relationship between disease activity and BMD 
values in patients. This is different from the 
hypothesis that the higher the disease activity, 
the lower the BMD value. Several factors 
influence the results of this study. Among them is 
a research design that uses a cross sectional 
study approach where disease activity and bone 
mineral density are measured at the same time. 
Changes in bone density take a long time while 
disease activity is a condition that can change in 
a short time. The change in BMD in AR patients 
who did not receive adequate therapy was 0.2% 
-1.2% per year. [27] In AR patients who have 
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normal BMD results at the beginning will change 
to osteopenia around 2-7 years.[21] This is 
different from the disease activity which can 
change every month. Several factors that affect 
bone mass in AR such as calcium 
supplementation, vitamin D levels, 
administration of bisphosphonate drugs, serum 
estradiol levels, and parathyroid hormone levels 
in this study cannot be controlled. [16, 33] 
In this study, there were no significant 
results between calcium levels and BMD values. 
This is different from the hypothesis where AR 
patients are suspected of having decreased 
calcium, thus affecting the low BMD value. These 
results are not in accordance with our hypothesis 
because the normal calcium levels in this study 
are caused by a process of calcium balance and 
homeostasis which is played by the 3 main 
mechanisms of intestinal absorption, renal 
reabsorption, and bone turnover. The main 
mechanism above is regulated by the interaction 
of parathyroid hormone, 1,25-
dihydroxyvitamins, calcium ions and their 
receptors in the intestines, kidneys. The 
homeostasis process aims to maintain normal 
plasma calcium levels. Intestinal and renal 
absorption of calcium stimulates bone formation 
and remodeling. On the other hand, if the 
absorption rate is reduced, it will stimulate bone 
reabsorption. [34, 35] The results of this study are 
consistent with previous studies where serum 
calcium levels did not affect the value of BMD. [35-
37] 
 In this study, there was a significant 
relationship between age and BMD values for 
Femur Neck (p = 0,043), Lumbar 3 (p = 0,017), and 
Lumbar 4 (p = 0,048) even though the patient's 
average age was 45,87 years. With a negative 
correlation direction, which indicates that the 
higher the age, the lower the BMD value. It is 
known that there is no substantial reduction in 
bone mass in men up to age 65 and women until 
menopause. [24-26] The results of this study are 
consistent with previous studies that in newly 
diagnosed AR patients with symptom duration 
<2 years, 11.3% showed osteoporosis and 24,7% 
had decreased bone mass density, even in 
younger AR patients aged 20-49 years, 2,4% had 
osteoporosis and 21,6% had low bone mass 
density. [21, 38] These results are consistent with 
the existing literature that AR increases the risk of 
decreased bone mass and osteoporosis. [22, 27]  
In this study, there was a significant 
relationship between BMI and bone mass density 
at the femur neck (p = 0,045) and the great 
trochanter (p = 0,018) with the r value at both 
locations which indicates that the greater the 
BMI value, the greater the value of BMD. These 
results are consistent with the literature that 
ideal BMI is associated with a good BMD value, 
this is because BMI itself is an independent risk 
factor for osteoporosis. [39] In addition, a study 
states that the ideal BMI is related to a healthy 
diet where nutrients such as calcium, protein, 
and other nutrients are consumed in sufficient 
quantities so that in the end, results in good BMD 
values. [40] In patients with AR, a chronic 
inflammatory disease, inflammatory mediators 
such as (TNF-α) and interleukin 6 (IL-6) are 
known to play a role in muscle proteolysis, 
mitochondrial muscle dysfunction, and insulin 
resistance. And TNF-α and IL-6 inhibition in AR 
patients will increase muscle mass and body 
weight. [41, 42] The results of this study are 
consistent with another study in which half of the 
patients with AR are likely to experience 
rheumatoid cachexia, a condition significantly 
associated with activity. disease and low hip BMD 
values. [43]
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C O N C L U S I O N 
 There was no correlation between 
disease activity and calcium levels and BMD 
values in AR patients. There was a correlation 
between age and BMI with BMD values in AR 
patients. (As shown in the Table 3) 
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